Cemiplimab


Cemiplimab is a monoclonal antibody drug for the treatment of squamous cell skin cancer, myeloma, and lung cancer.
In Sept 2018 it was approved by the US FDA for treating "patients with metastatic cutaneous squamous cell carcinoma or locally advanced CSCC who are not candidates for curative surgery or curative radiation".

Mechanism of action

It targets PD-1 so it acts as a checkpoint inhibitor.